Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-dose melphalan treatment significantly increases mutational burden at relapse in multiple myeloma.
Samur MK, Roncador M, Aktas Samur A, Fulciniti M, Bazarbachi AH, Szalat R, Shammas MA, Sperling AS, Richardson PG, Magrangeas F, Minvielle S, Perrot A, Corre J, Moreau P, Thakurta A, Parmigiani G, Anderson KC, Avet-Loiseau H, Munshi NC. Samur MK, et al. Among authors: fulciniti m. Blood. 2023 Apr 6;141(14):1724-1736. doi: 10.1182/blood.2022017094. Blood. 2023. PMID: 36603186 Free PMC article.
Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma.
Zeid R, Lawlor MA, Poon E, Reyes JM, Fulciniti M, Lopez MA, Scott TG, Nabet B, Erb MA, Winter GE, Jacobson Z, Polaski DR, Karlin KL, Hirsch RA, Munshi NP, Westbrook TF, Chesler L, Lin CY, Bradner JE. Zeid R, et al. Among authors: fulciniti m. Nat Genet. 2018 Apr;50(4):515-523. doi: 10.1038/s41588-018-0044-9. Epub 2018 Jan 29. Nat Genet. 2018. PMID: 29379199 Free PMC article.
Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications.
Shammas MA, Neri P, Koley H, Batchu RB, Bertheau RC, Munshi V, Prabhala R, Fulciniti M, Tai YT, Treon SP, Goyal RK, Anderson KC, Munshi NC. Shammas MA, et al. Among authors: fulciniti m. Blood. 2006 Oct 15;108(8):2804-10. doi: 10.1182/blood-2006-05-022814. Epub 2006 Jun 29. Blood. 2006. PMID: 16809610 Free PMC article.
Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).
Chauhan D, Neri P, Velankar M, Podar K, Hideshima T, Fulciniti M, Tassone P, Raje N, Mitsiades C, Mitsiades N, Richardson P, Zawel L, Tran M, Munshi N, Anderson KC. Chauhan D, et al. Among authors: fulciniti m. Blood. 2007 Feb 1;109(3):1220-7. doi: 10.1182/blood-2006-04-015149. Epub 2006 Oct 10. Blood. 2007. PMID: 17032924 Free PMC article.
Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.
Tai YT, Fulciniti M, Hideshima T, Song W, Leiba M, Li XF, Rumizen M, Burger P, Morrison A, Podar K, Chauhan D, Tassone P, Richardson P, Munshi NC, Ghobrial IM, Anderson KC. Tai YT, et al. Among authors: fulciniti m. Blood. 2007 Sep 1;110(5):1656-63. doi: 10.1182/blood-2007-03-081240. Epub 2007 May 17. Blood. 2007. PMID: 17510321 Free PMC article. Clinical Trial.
Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo.
Shammas MA, Koley H, Bertheau RC, Neri P, Fulciniti M, Tassone P, Blotta S, Protopopov A, Mitsiades C, Batchu RB, Anderson KC, Chin A, Gryaznov S, Munshi NC. Shammas MA, et al. Among authors: fulciniti m. Leukemia. 2008 Jul;22(7):1410-8. doi: 10.1038/leu.2008.81. Epub 2008 May 1. Leukemia. 2008. PMID: 18449204 Free PMC article.
96 results